Short answer
Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on August 26, 2026 reporting Item 8.01 (Other Events). FDA approval of RASONQUE, daraxonrasib, for previously treated metastatic pancreatic adenocarcinoma.
Revolution Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA approval of RASONQUE, daraxonrasib, for previously treated metastatic pancreatic adenocarcinoma
- Approval supported by RASolute 302, a randomized Phase 3 trial versus investigator-selected chemotherapy
- U.S. commercial launch underway with once-daily oral tablets available to eligible patients
- Wholesale acquisition cost: $39,800 per 30-day supply, establishing a significant commercial revenue opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Revolution Medicines Inc 8-K filings
Get the next RVMD 8-K as it lands
Follow RVMD for push alerts, or ask the research agent what this filing means.